Insider · CIK 0001834411
Andrew Booth
Files at ABCL (AbCellera Biologics Inc.). First filing Feb 27, 2026, latest Aug 14, 2026.
In brief
Andrew Booth files SEC Form 4 as CFO at ABCL (AbCellera Biologics Inc.). Since Feb 27, 2026, Andrew Booth has reported 2 open-market buys worth $530k and 0 open-market sells worth $0, the latest filed on Aug 14, 2026.
A track record needs three past buys with six months of prices behind them; Andrew Booth has 1, so none is measured yet.
The newest scored trade: bought $384k of ABCL on Aug 14, 2026, filed Aug 14, 2026, scored 56 (moderate). In the last 12 months: 2 buys worth $530k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABCL: AbCellera Biologics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | AbCellera Biologics Inc. | $384k 37,200 shares | +8% | +309% from low0% from high | |
| 55Moderate | AbCellera Biologics Inc. | $146k 42,600 shares | +28% | +87% from low-41% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +37,200 | $10.32 | $384k | 482,800 | Aug 14, 2026 |
| Jun 3, 2026 | ABCL AbCellera Biologics Inc. | MOption exercise Common Shares | +250,000 | $0.19 | $48k | 445,600 | Jun 3, 2026 |
| Jun 3, 2026 | ABCL AbCellera Biologics Inc. | MOption exercise Share option (right to buy)derivative | -250,000 | $0.00 | $0 | 8,501,849 | Jun 3, 2026 |
| Feb 27, 2026 | ABCL AbCellera Biologics Inc. | POpen-market purchase Common Shares | +42,600 | $3.42 | $146k | 195,600 | Feb 27, 2026 |
| Jan 1, 2026 | ABCL AbCellera Biologics Inc. | AGrant or award Share option (right to buy)derivative | +808,898 | $0.00 | $0 | 8,751,849 | Jan 5, 2026 |
| Jan 1, 2025 | ABCL AbCellera Biologics Inc. | AGrant or award Share option (right to buy)derivative | +1,352,054 | $0.00 | $0 | 7,942,951 | Jan 3, 2025 |
Questions about Andrew Booth
Answered from the filings on this page, as of the latest one.
Is Andrew Booth buying or selling?
In the last 12 months Andrew Booth reported 2 open-market buys worth $530k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $384k of ABCL on Aug 14, 2026. Grants, option exercises and tax withholding are not counted.
How did Andrew Booth's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew Booth has 1.
Where does Andrew Booth file Form 4?
Andrew Booth has filed Form 4 at ABCL (AbCellera Biologics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.